Divergence in recommendations, but unity in direction: 4 tyre stocks with upside potential of up to 30%

This week, two real estate companies announced that they have sold out their real estate projects. What was worth noting, the overall size of the project, time in which they were sold and the price point at which they were lapped up. Both, real estate prices and stocks of real estate have seen a revival for last three years, if above events are anything to go by than probably, it appears that the demand continues to be strong in some pockets. Given the fact that the operating matrix of the real estate industry is such that debt element will present, it would be worthwhile to stay with large players who have either strong parent group or have track record where they have survived the slowdown without piling on much debt on the balance sheet. Also stay focussed on pockets where income profile of consumer is better.

One change for making higher provision for unsecured loans and we see all the NBFC stocks tumbling. But four weeks later what is the situation, no one on the street is even talking about it and stocks have crossed the level when the announcement was made. The fact is that some regulatory measures are indicators of overall growth potential which the regulator is just trying to moderate in order to avoid overheating of some segment of industry. The other question is that an industry like NBFC which is bound to grow given the fact that capital was, is and will remain a scarce commodity, which are the benchmark which one should use to take exposure with a long term perspective.

It is not very common to see tailwinds emerging for an industry at a time when it is ideal to own stocks from that space. But in the case of pharmaceutical companies, tailwinds have emerged at a time when valuations of the overall market are expensive and it makes sense to look at pharma stocks as they tend to act as defensive stocks in volatile times with bearish bias. However they should not be clubbed together; each company has its own operating matrix. A company which has a strong domestic brand in the generic drugs segment, will not be getting impacted by what is happening in the US pharma market or what USFDA does. But yes, if it might be impacted by what happens in China.

While the mid and small cap saw sharp corrections on Monday, the fact is speciality chemical space has been in a very different kind of correction for the last two years. In the last five years many segments of the chemical and specialty chemical sector had been coming into focus. They stay in the limelight for some time, then as too much money chases them which makes their valuations move up sharply and then a long phase of correction after which strong players are able to move upward much faster. While they come under the broad umbrella word of “Chemical sector” the fact is that each specialty chemical company is literally an industry itself with its own operating matrix of supply chain and demand. We look at the 6 stocks, including 4 stocks where analysts have “hold” recommendation at a time when chinese headwinds are blowing.